Pronounced Acute Immunosuppression in vivo Mediated by HIV Tat Challenge

HIV infection is accompanied by an early immune dysfunction limiting host control of virus and likely contributing to difficulties in achieving a successful vaccine against HIV. We report here that the HIV Tat protein is strongly immunosuppressive, both immediately after immunization of mice with so...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Proceedings of the National Academy of Sciences - PNAS 1999-09, Vol.96 (19), p.10842-10847
Hauptverfasser: Cohen, Sandra S., Li, Chiang, Ding, Linna, Cao, Yunzhen, Pardee, Arthur B., Shevach, Ethan M., Cohen, David I.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 10847
container_issue 19
container_start_page 10842
container_title Proceedings of the National Academy of Sciences - PNAS
container_volume 96
creator Cohen, Sandra S.
Li, Chiang
Ding, Linna
Cao, Yunzhen
Pardee, Arthur B.
Shevach, Ethan M.
Cohen, David I.
description HIV infection is accompanied by an early immune dysfunction limiting host control of virus and likely contributing to difficulties in achieving a successful vaccine against HIV. We report here that the HIV Tat protein is strongly immunosuppressive, both immediately after immunization of mice with soluble protein (sTat), and in seroconverting humans, and propose that Tat-induced suppression cripples immune surveillance to HIV infection. We show that macrophages are sensitive to sTat stimulation at concentrations 1,000-fold lower (500 pM) than T cells, and this stimulation is accompanied by the immunosuppressive induction of Fas ligand on the macrophage. T cell proliferative defects induced by sTat in vitro can be completely (at lower concentrations of sTat) or partially (at higher concentrations) reversed by antagonists to Fas/Fas ligand interaction. We further report a method to preserve immunogenicity while inactivating Tat immunosuppression through oxidation, which advances the use of oxidized Tat as a component of an anti-HIV vaccine. These observations define additional methods to study the immunosuppressive functions of sTat that now may be rapidly applied to primary isolates from individuals with differing clinical courses. Our findings have immediate relevance for vaccine development, by describing and supporting a strategy that includes inactivated sTat in a multicomponent, anti-HIV vaccine.
doi_str_mv 10.1073/pnas.96.19.10842
format Article
fullrecord <record><control><sourceid>jstor_proqu</sourceid><recordid>TN_cdi_proquest_journals_201383561</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><jstor_id>48840</jstor_id><sourcerecordid>48840</sourcerecordid><originalsourceid>FETCH-LOGICAL-c524t-2b203b738bbd6523fc434748d2fef5569728d35638652d0a4e99a93187ccc12d3</originalsourceid><addsrcrecordid>eNqFkc1v1DAUxC0EokvhjjhAxAFxyfL8kdiWuFQrYFcqgkPhajmO02aV2KntrOh_j7e7VC0HOFn2_Gbk9wahlxiWGDj9MDkdl7JeYpnvgpFHaIFB4rJmEh6jBQDhZX5mJ-hZjFsAkJWAp-gEAxOVxHSB1t-Dd352xrbFmZmTLTbjODsf52kKNsbeu6J3xa7f-eKrbXudMtjcFOvNz-JCp2J1pYfBukv7HD3p9BDti-N5in58_nSxWpfn375sVmfnpakISyVpCNCGU9E0bV0R2hlGGWeiJZ3tqqqWnIiWVjUVWW1BMyullhQLbozBpKWn6OMhd5qb0bbGuhT0oKbQjzrcKK979VBx_ZW69DuFueSQ7e-O9uCvZxuTGvto7DBoZ_0cFQdgTAj5XxBzBpzdJr79C9z6Obi8A0UAU5GHwRmCA2SCjzHY7u7DGNS-SrWvUslaYaluq8yW1_cHvWc4dJeBN0dgb_0jP4x4_29CdfMwJPsrZfTVAd3G5MMdm1fBgP4G6gi7Eg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>201383561</pqid></control><display><type>article</type><title>Pronounced Acute Immunosuppression in vivo Mediated by HIV Tat Challenge</title><source>MEDLINE</source><source>Jstor Complete Legacy</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><source>Free Full-Text Journals in Chemistry</source><creator>Cohen, Sandra S. ; Li, Chiang ; Ding, Linna ; Cao, Yunzhen ; Pardee, Arthur B. ; Shevach, Ethan M. ; Cohen, David I.</creator><creatorcontrib>Cohen, Sandra S. ; Li, Chiang ; Ding, Linna ; Cao, Yunzhen ; Pardee, Arthur B. ; Shevach, Ethan M. ; Cohen, David I.</creatorcontrib><description>HIV infection is accompanied by an early immune dysfunction limiting host control of virus and likely contributing to difficulties in achieving a successful vaccine against HIV. We report here that the HIV Tat protein is strongly immunosuppressive, both immediately after immunization of mice with soluble protein (sTat), and in seroconverting humans, and propose that Tat-induced suppression cripples immune surveillance to HIV infection. We show that macrophages are sensitive to sTat stimulation at concentrations 1,000-fold lower (500 pM) than T cells, and this stimulation is accompanied by the immunosuppressive induction of Fas ligand on the macrophage. T cell proliferative defects induced by sTat in vitro can be completely (at lower concentrations of sTat) or partially (at higher concentrations) reversed by antagonists to Fas/Fas ligand interaction. We further report a method to preserve immunogenicity while inactivating Tat immunosuppression through oxidation, which advances the use of oxidized Tat as a component of an anti-HIV vaccine. These observations define additional methods to study the immunosuppressive functions of sTat that now may be rapidly applied to primary isolates from individuals with differing clinical courses. Our findings have immediate relevance for vaccine development, by describing and supporting a strategy that includes inactivated sTat in a multicomponent, anti-HIV vaccine.</description><identifier>ISSN: 0027-8424</identifier><identifier>EISSN: 1091-6490</identifier><identifier>DOI: 10.1073/pnas.96.19.10842</identifier><identifier>PMID: 10485913</identifier><language>eng</language><publisher>United States: National Academy of Sciences of the United States of America</publisher><subject>AIDS Vaccines - metabolism ; AIDS/HIV ; Animals ; Antibodies ; Antigens ; Biological Sciences ; Cells, Cultured ; Disease ; Dose-Response Relationship, Drug ; Fas antigen ; Fas Ligand Protein ; FasL protein ; Flow Cytometry ; Gene Products, tat - immunology ; Gene Products, tat - metabolism ; Gene Products, tat - pharmacology ; HIV ; HIV infections ; HIV Infections - immunology ; HIV Infections - metabolism ; Human immunodeficiency virus ; Humans ; Immune Tolerance - physiology ; Immunoblotting ; Immunology ; Immunosuppression ; Leukocytes, Mononuclear - immunology ; Leukocytes, Mononuclear - metabolism ; Macrophages - drug effects ; Macrophages - immunology ; Macrophages - metabolism ; Membrane Glycoproteins - antagonists &amp; inhibitors ; Membrane Glycoproteins - metabolism ; Mice ; Mice, Inbred BALB C ; Monocytes ; Proteins ; Recombinant Proteins - pharmacology ; T lymphocytes ; T-Lymphocytes, Helper-Inducer - drug effects ; tat Gene Products, Human Immunodeficiency Virus ; Tetanus ; Vaccination ; Viruses</subject><ispartof>Proceedings of the National Academy of Sciences - PNAS, 1999-09, Vol.96 (19), p.10842-10847</ispartof><rights>Copyright 1993-1999 The National Academy of Sciences of the United States of America</rights><rights>Copyright National Academy of Sciences Sep 14, 1999</rights><rights>Copyright © 1999, The National Academy of Sciences 1999</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c524t-2b203b738bbd6523fc434748d2fef5569728d35638652d0a4e99a93187ccc12d3</citedby><cites>FETCH-LOGICAL-c524t-2b203b738bbd6523fc434748d2fef5569728d35638652d0a4e99a93187ccc12d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Uhttp://www.pnas.org/content/96/19.cover.gif</thumbnail><linktopdf>$$Uhttps://www.jstor.org/stable/pdf/48840$$EPDF$$P50$$Gjstor$$H</linktopdf><linktohtml>$$Uhttps://www.jstor.org/stable/48840$$EHTML$$P50$$Gjstor$$H</linktohtml><link.rule.ids>230,314,723,776,780,799,881,27903,27904,53769,53771,57995,58228</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/10485913$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Cohen, Sandra S.</creatorcontrib><creatorcontrib>Li, Chiang</creatorcontrib><creatorcontrib>Ding, Linna</creatorcontrib><creatorcontrib>Cao, Yunzhen</creatorcontrib><creatorcontrib>Pardee, Arthur B.</creatorcontrib><creatorcontrib>Shevach, Ethan M.</creatorcontrib><creatorcontrib>Cohen, David I.</creatorcontrib><title>Pronounced Acute Immunosuppression in vivo Mediated by HIV Tat Challenge</title><title>Proceedings of the National Academy of Sciences - PNAS</title><addtitle>Proc Natl Acad Sci U S A</addtitle><description>HIV infection is accompanied by an early immune dysfunction limiting host control of virus and likely contributing to difficulties in achieving a successful vaccine against HIV. We report here that the HIV Tat protein is strongly immunosuppressive, both immediately after immunization of mice with soluble protein (sTat), and in seroconverting humans, and propose that Tat-induced suppression cripples immune surveillance to HIV infection. We show that macrophages are sensitive to sTat stimulation at concentrations 1,000-fold lower (500 pM) than T cells, and this stimulation is accompanied by the immunosuppressive induction of Fas ligand on the macrophage. T cell proliferative defects induced by sTat in vitro can be completely (at lower concentrations of sTat) or partially (at higher concentrations) reversed by antagonists to Fas/Fas ligand interaction. We further report a method to preserve immunogenicity while inactivating Tat immunosuppression through oxidation, which advances the use of oxidized Tat as a component of an anti-HIV vaccine. These observations define additional methods to study the immunosuppressive functions of sTat that now may be rapidly applied to primary isolates from individuals with differing clinical courses. Our findings have immediate relevance for vaccine development, by describing and supporting a strategy that includes inactivated sTat in a multicomponent, anti-HIV vaccine.</description><subject>AIDS Vaccines - metabolism</subject><subject>AIDS/HIV</subject><subject>Animals</subject><subject>Antibodies</subject><subject>Antigens</subject><subject>Biological Sciences</subject><subject>Cells, Cultured</subject><subject>Disease</subject><subject>Dose-Response Relationship, Drug</subject><subject>Fas antigen</subject><subject>Fas Ligand Protein</subject><subject>FasL protein</subject><subject>Flow Cytometry</subject><subject>Gene Products, tat - immunology</subject><subject>Gene Products, tat - metabolism</subject><subject>Gene Products, tat - pharmacology</subject><subject>HIV</subject><subject>HIV infections</subject><subject>HIV Infections - immunology</subject><subject>HIV Infections - metabolism</subject><subject>Human immunodeficiency virus</subject><subject>Humans</subject><subject>Immune Tolerance - physiology</subject><subject>Immunoblotting</subject><subject>Immunology</subject><subject>Immunosuppression</subject><subject>Leukocytes, Mononuclear - immunology</subject><subject>Leukocytes, Mononuclear - metabolism</subject><subject>Macrophages - drug effects</subject><subject>Macrophages - immunology</subject><subject>Macrophages - metabolism</subject><subject>Membrane Glycoproteins - antagonists &amp; inhibitors</subject><subject>Membrane Glycoproteins - metabolism</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Monocytes</subject><subject>Proteins</subject><subject>Recombinant Proteins - pharmacology</subject><subject>T lymphocytes</subject><subject>T-Lymphocytes, Helper-Inducer - drug effects</subject><subject>tat Gene Products, Human Immunodeficiency Virus</subject><subject>Tetanus</subject><subject>Vaccination</subject><subject>Viruses</subject><issn>0027-8424</issn><issn>1091-6490</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1999</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1v1DAUxC0EokvhjjhAxAFxyfL8kdiWuFQrYFcqgkPhajmO02aV2KntrOh_j7e7VC0HOFn2_Gbk9wahlxiWGDj9MDkdl7JeYpnvgpFHaIFB4rJmEh6jBQDhZX5mJ-hZjFsAkJWAp-gEAxOVxHSB1t-Dd352xrbFmZmTLTbjODsf52kKNsbeu6J3xa7f-eKrbXudMtjcFOvNz-JCp2J1pYfBukv7HD3p9BDti-N5in58_nSxWpfn375sVmfnpakISyVpCNCGU9E0bV0R2hlGGWeiJZ3tqqqWnIiWVjUVWW1BMyullhQLbozBpKWn6OMhd5qb0bbGuhT0oKbQjzrcKK979VBx_ZW69DuFueSQ7e-O9uCvZxuTGvto7DBoZ_0cFQdgTAj5XxBzBpzdJr79C9z6Obi8A0UAU5GHwRmCA2SCjzHY7u7DGNS-SrWvUslaYaluq8yW1_cHvWc4dJeBN0dgb_0jP4x4_29CdfMwJPsrZfTVAd3G5MMdm1fBgP4G6gi7Eg</recordid><startdate>19990914</startdate><enddate>19990914</enddate><creator>Cohen, Sandra S.</creator><creator>Li, Chiang</creator><creator>Ding, Linna</creator><creator>Cao, Yunzhen</creator><creator>Pardee, Arthur B.</creator><creator>Shevach, Ethan M.</creator><creator>Cohen, David I.</creator><general>National Academy of Sciences of the United States of America</general><general>National Acad Sciences</general><general>National Academy of Sciences</general><general>The National Academy of Sciences</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7SN</scope><scope>7SS</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U9</scope><scope>8FD</scope><scope>C1K</scope><scope>FR3</scope><scope>H94</scope><scope>M7N</scope><scope>P64</scope><scope>RC3</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>19990914</creationdate><title>Pronounced Acute Immunosuppression in vivo Mediated by HIV Tat Challenge</title><author>Cohen, Sandra S. ; Li, Chiang ; Ding, Linna ; Cao, Yunzhen ; Pardee, Arthur B. ; Shevach, Ethan M. ; Cohen, David I.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c524t-2b203b738bbd6523fc434748d2fef5569728d35638652d0a4e99a93187ccc12d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1999</creationdate><topic>AIDS Vaccines - metabolism</topic><topic>AIDS/HIV</topic><topic>Animals</topic><topic>Antibodies</topic><topic>Antigens</topic><topic>Biological Sciences</topic><topic>Cells, Cultured</topic><topic>Disease</topic><topic>Dose-Response Relationship, Drug</topic><topic>Fas antigen</topic><topic>Fas Ligand Protein</topic><topic>FasL protein</topic><topic>Flow Cytometry</topic><topic>Gene Products, tat - immunology</topic><topic>Gene Products, tat - metabolism</topic><topic>Gene Products, tat - pharmacology</topic><topic>HIV</topic><topic>HIV infections</topic><topic>HIV Infections - immunology</topic><topic>HIV Infections - metabolism</topic><topic>Human immunodeficiency virus</topic><topic>Humans</topic><topic>Immune Tolerance - physiology</topic><topic>Immunoblotting</topic><topic>Immunology</topic><topic>Immunosuppression</topic><topic>Leukocytes, Mononuclear - immunology</topic><topic>Leukocytes, Mononuclear - metabolism</topic><topic>Macrophages - drug effects</topic><topic>Macrophages - immunology</topic><topic>Macrophages - metabolism</topic><topic>Membrane Glycoproteins - antagonists &amp; inhibitors</topic><topic>Membrane Glycoproteins - metabolism</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Monocytes</topic><topic>Proteins</topic><topic>Recombinant Proteins - pharmacology</topic><topic>T lymphocytes</topic><topic>T-Lymphocytes, Helper-Inducer - drug effects</topic><topic>tat Gene Products, Human Immunodeficiency Virus</topic><topic>Tetanus</topic><topic>Vaccination</topic><topic>Viruses</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cohen, Sandra S.</creatorcontrib><creatorcontrib>Li, Chiang</creatorcontrib><creatorcontrib>Ding, Linna</creatorcontrib><creatorcontrib>Cao, Yunzhen</creatorcontrib><creatorcontrib>Pardee, Arthur B.</creatorcontrib><creatorcontrib>Shevach, Ethan M.</creatorcontrib><creatorcontrib>Cohen, David I.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium &amp; Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Ecology Abstracts</collection><collection>Entomology Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>Engineering Research Database</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cohen, Sandra S.</au><au>Li, Chiang</au><au>Ding, Linna</au><au>Cao, Yunzhen</au><au>Pardee, Arthur B.</au><au>Shevach, Ethan M.</au><au>Cohen, David I.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Pronounced Acute Immunosuppression in vivo Mediated by HIV Tat Challenge</atitle><jtitle>Proceedings of the National Academy of Sciences - PNAS</jtitle><addtitle>Proc Natl Acad Sci U S A</addtitle><date>1999-09-14</date><risdate>1999</risdate><volume>96</volume><issue>19</issue><spage>10842</spage><epage>10847</epage><pages>10842-10847</pages><issn>0027-8424</issn><eissn>1091-6490</eissn><abstract>HIV infection is accompanied by an early immune dysfunction limiting host control of virus and likely contributing to difficulties in achieving a successful vaccine against HIV. We report here that the HIV Tat protein is strongly immunosuppressive, both immediately after immunization of mice with soluble protein (sTat), and in seroconverting humans, and propose that Tat-induced suppression cripples immune surveillance to HIV infection. We show that macrophages are sensitive to sTat stimulation at concentrations 1,000-fold lower (500 pM) than T cells, and this stimulation is accompanied by the immunosuppressive induction of Fas ligand on the macrophage. T cell proliferative defects induced by sTat in vitro can be completely (at lower concentrations of sTat) or partially (at higher concentrations) reversed by antagonists to Fas/Fas ligand interaction. We further report a method to preserve immunogenicity while inactivating Tat immunosuppression through oxidation, which advances the use of oxidized Tat as a component of an anti-HIV vaccine. These observations define additional methods to study the immunosuppressive functions of sTat that now may be rapidly applied to primary isolates from individuals with differing clinical courses. Our findings have immediate relevance for vaccine development, by describing and supporting a strategy that includes inactivated sTat in a multicomponent, anti-HIV vaccine.</abstract><cop>United States</cop><pub>National Academy of Sciences of the United States of America</pub><pmid>10485913</pmid><doi>10.1073/pnas.96.19.10842</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0027-8424
ispartof Proceedings of the National Academy of Sciences - PNAS, 1999-09, Vol.96 (19), p.10842-10847
issn 0027-8424
1091-6490
language eng
recordid cdi_proquest_journals_201383561
source MEDLINE; Jstor Complete Legacy; PubMed Central; Alma/SFX Local Collection; Free Full-Text Journals in Chemistry
subjects AIDS Vaccines - metabolism
AIDS/HIV
Animals
Antibodies
Antigens
Biological Sciences
Cells, Cultured
Disease
Dose-Response Relationship, Drug
Fas antigen
Fas Ligand Protein
FasL protein
Flow Cytometry
Gene Products, tat - immunology
Gene Products, tat - metabolism
Gene Products, tat - pharmacology
HIV
HIV infections
HIV Infections - immunology
HIV Infections - metabolism
Human immunodeficiency virus
Humans
Immune Tolerance - physiology
Immunoblotting
Immunology
Immunosuppression
Leukocytes, Mononuclear - immunology
Leukocytes, Mononuclear - metabolism
Macrophages - drug effects
Macrophages - immunology
Macrophages - metabolism
Membrane Glycoproteins - antagonists & inhibitors
Membrane Glycoproteins - metabolism
Mice
Mice, Inbred BALB C
Monocytes
Proteins
Recombinant Proteins - pharmacology
T lymphocytes
T-Lymphocytes, Helper-Inducer - drug effects
tat Gene Products, Human Immunodeficiency Virus
Tetanus
Vaccination
Viruses
title Pronounced Acute Immunosuppression in vivo Mediated by HIV Tat Challenge
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-26T01%3A58%3A16IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-jstor_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Pronounced%20Acute%20Immunosuppression%20in%20vivo%20Mediated%20by%20HIV%20Tat%20Challenge&rft.jtitle=Proceedings%20of%20the%20National%20Academy%20of%20Sciences%20-%20PNAS&rft.au=Cohen,%20Sandra%20S.&rft.date=1999-09-14&rft.volume=96&rft.issue=19&rft.spage=10842&rft.epage=10847&rft.pages=10842-10847&rft.issn=0027-8424&rft.eissn=1091-6490&rft_id=info:doi/10.1073/pnas.96.19.10842&rft_dat=%3Cjstor_proqu%3E48840%3C/jstor_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=201383561&rft_id=info:pmid/10485913&rft_jstor_id=48840&rfr_iscdi=true